US2020377850A1PendingUtilityA1
Seed train processes and uses thereof
Est. expiryJun 9, 2034(~7.9 yrs left)· nominal 20-yr term from priority
C12N 5/0031C12M 29/10C12M 27/16C12M 23/58C12M 23/28C12N 9/00C12N 5/0682C12N 5/0037C12P 21/00C12N 2511/00C12N 2510/02C12N 5/0062C12N 5/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are seed train processes and methods of producing a recombinant protein that include the use of these seed train processes.
Claims
exact text as granted — not AI-modified1 .- 33 . (canceled)
34 . A method of producing a recombinant protein comprising:
(a) disposing a plurality of recombinant mammalian cells into a first culture medium comprised within a vessel to provide a first cell culture; (b) batch culturing the first cell culture to a cell density range of about 1.0×10 6 cells/mL to about 5.0×10 6 cells/mL; (c) disposing a volume of the first cell culture medium of (b) into a second culture medium comprised within a perfusion bioreactor to provide a second cell culture with an initial cell density in a range of about 0.25×10 6 cells/mL to about 0.5×10 6 cells/mL; (d) perfusion culturing the second cell culture to a cell density range of between about 5×10 6 cells/mL to about 60×10 6 cells/mL; (e) disposing a volume of the second cell culture of (d) into a third culture medium comprised within a production bioreactor to provide a production cell culture with an initial cell density in a range of about 0.25×10 6 cells/mL to about 8×10 6 cells/mL; (f) perfusion culturing the production cell culture under conditions that allow the recombinant mammalian cells to secrete a recombinant protein; (g) harvesting the recombinant protein from the production cell culture; and (h) isolating the recombinant protein from the third culture medium.
35 . The method of claim 34 , wherein disposing the plurality of recombinant mammalian cells in (a) comprises:
thawing a frozen cell bank; and disposing a volume of the thawed cell bank into the first culture medium.
36 .- 38 . (canceled)
39 . The method of claim 34 , wherein disposing the plurality of recombinant mammalian cells in (a) comprises disposing a volume of a third cell culture comprising the plurality of recombinant mammalian cells into the first culture medium.
40 . The method of claim 39 , further comprising:
(1) disposing a plurality of the recombinant mammalian cells into a fourth culture medium comprised within a vessel to provide the third cell culture; (2) batch culturing the third cell culture in (1) to a cell density range of about 1.0×10 6 cells/mL to about 5.0×10 6 cells/mL, wherein a volume of the third cell culture in (2) is disposed into the first culture medium in (a).
41 .- 42 . (canceled)
43 . The method of claim 40 , wherein disposing the plurality of the recombinant mammalian cells in (1) comprises:
thawing a frozen cell bank; and disposing a volume of the thawed cell bank into the fourth culture medium.
44 .- 47 . (canceled)
48 . The method of claim 34 , wherein the first cell culture in (a) has a volume range of about 1.0 L to about 50 L.
49 . (canceled)
50 . The method of claim 34 , wherein the second cell culture in (c) has a volume range of about 5 L to about 600 L.
51 . (canceled)
52 . The method of claim 34 , wherein the production cell culture in (e) has a volume range of about 50 L to about 20,000 L.
53 . (canceled)
54 . The method of claim 40 , wherein the fourth culture medium in (1) has a volume range of about 500 mL to about 20 L.
55 . (canceled)
56 . The method of claim 34 , wherein the vessel in (a) has an internal volume range of about 1.5 L to about 100 L.
57 . (canceled)
58 . The method of claim 34 , wherein the perfusion bioreactor in (c) has an internal volume range of about 7.5 L to about 1,000 L.
59 . (canceled)
60 . The method of claim 34 , wherein the production bioreactor in (e) has an internal volume range of about 150 L to about 25,000 L.
61 . (canceled)
62 . The method of claim 40 , wherein the vessel in (1) has an internal volume range of about 1 L to about 40 L.
63 . (canceled)
64 . The method of claim 34 , wherein the perfusion culturing in (c) is performed using a perfusion bioreactor equipped with an alternating tangential flow filtration device.
65 . The method of claim 34 , wherein the initial cell density in (e) is in a range of about 2.0×10 6 cells/mL to about 8×10 6 cells/mL
66 . The method of claim 34 , wherein the initial cell density in (e) is at least 10% of the steady state production cell density.
67 . (canceled)
68 . The method of claim 66 , wherein the steady state production cell density is between 5×10 6 cells/mL to about 50×10 6 cells/mL.
69 . (canceled)
70 . The method of claim 34 , wherein the perfusion culturing in (f) results in the production cell culture reaching the steady state production cell density in a period of between about 1 day to about 10 days.
71 .- 74 . (canceled)
75 . The method of claim 34 , wherein the isolating is performed using an integrated and continuous process.
76 . The method of claim 34 , further comprising formulating the isolated recombinant protein into a pharmaceutical agent.Join the waitlist — get patent alerts
Track US2020377850A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.